{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:01:56Z","timestamp":1774418516029,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04163-x","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:39:30Z","timestamp":1770449970000},"page":"1138-1150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SEOM\u2013GEMCAD\u2013TTD clinical guidelines for anal cancer (2025)"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7509-146X","authenticated-orcid":false,"given":"M\u00f3nica Guillot","family":"Morales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Fern\u00e1ndez","family":"Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julen","family":"Fern\u00e1ndez-Plana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael Ghanem","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia Gil","family":"Raga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jer\u00f3nimo","family":"Jim\u00e9nez-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio Juez","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan Maurel","family":"Santasusana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Polo","family":"Marqu\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma Auxiliadora","family":"G\u00f3mez-Espa\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"4163_CR1","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.3390\/curroncol30030246","volume":"30","author":"TA Gondal","year":"2023","unstructured":"Gondal TA, Chaudhary N, Bajwa H, Rauf A, Le D, Ahmed S. Anal cancer: the past, present and future. Curr Oncol. 2023;30:3232. https:\/\/doi.org\/10.3390\/curroncol30030246.","journal-title":"Curr Oncol"},{"key":"4163_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","volume":"32","author":"S Rao","year":"2021","unstructured":"Rao S, Guren MG, Khan K, Brown G, Renehan AG, Steigen SE, et al. Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2021;32:1087\u2013100. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.015.","journal-title":"Ann Oncol"},{"key":"4163_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1086\/656735","volume":"51","author":"AR Khan","year":"2010","unstructured":"Khan AR, Khan S, Zimmerman V, Baddour LM, Tleyjeh IM. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis. 2010;51:1147\u201356. https:\/\/doi.org\/10.1086\/656735.","journal-title":"Clin Infect Dis"},{"key":"4163_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/jnci\/djz219","volume":"112","author":"AA Deshmukh","year":"2020","unstructured":"Deshmukh AA, Suk R, Shiels MS, Sonawane K, Nyitray AG, Liu Y, et al. Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001\u20132015. J Natl Cancer Inst. 2020;112:829\u201338. https:\/\/doi.org\/10.1093\/jnci\/djz219.","journal-title":"J Natl Cancer Inst"},{"key":"4163_CR5","unstructured":"GLOBOCAN. International Agency for Research on Cancer. World Health Organization 2022. [Internet]. [cited 2025 Oct 25]. https:\/\/gco.iarc.who.int\/today\/. Accessed 25 Oct 2025"},{"key":"4163_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1473-3099(21)00327-3","volume":"22","author":"SE Goldstone","year":"2022","unstructured":"Goldstone SE, Giuliano AR, Palefsky JM, Lazcano-Ponce E, Penny ME, Cabello RE, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022;22:413\u201325. https:\/\/doi.org\/10.1016\/S1473-3099(21)00327-3.","journal-title":"Lancet Infect Dis"},{"key":"4163_CR7","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1056\/NEJMoa2201048","volume":"386","author":"JM Palefsky","year":"2022","unstructured":"Palefsky JM, Lee JY, Jay N, Goldstone SE, Darragh TM, Dunlevy HA, et al. Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer. N Engl J Med. 2022;386:2273\u201382. https:\/\/doi.org\/10.1056\/NEJMoa2201048.","journal-title":"N Engl J Med"},{"key":"4163_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13244-022-01348-8","volume":"14","author":"N Bogveradze","year":"2023","unstructured":"Bogveradze N, Snaebjornsson P, Grotenhuis BA, van Triest B, Lahaye MJ, Maas M, et al. MRI anatomy of the rectum: key concepts important for rectal cancer staging and treatment planning. Insights Imaging. 2023;14:13. https:\/\/doi.org\/10.1186\/s13244-022-01348-8.","journal-title":"Insights Imaging"},{"key":"4163_CR9","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.2967\/jnumed.124.267626","volume":"65","author":"V Combet-Curt","year":"2024","unstructured":"Combet-Curt V, Buchalet C, Le Malicot K, Lemanski C, Deshayes E, Bonichon-Lamichhane N, et al. Prognostic value of 18F-FDG PET\/CT assessment after radiotherapy of squamous cell carcinoma of the anus in patients from the National Multicentric Cohort FFCD-ANABASE. J Nucl Med. 2024;65:1194\u2013201. https:\/\/doi.org\/10.2967\/jnumed.124.267626.","journal-title":"J Nucl Med"},{"key":"4163_CR10","volume-title":"TNM classification of malignant tumours","year":"2025","unstructured":"Brierley J, van Eycken E, Rous BA, Giuliani M, O\u2019Sullivan B, editors. TNM classification of malignant tumours. 9th ed. Hoboken, NJ: Wiley; 2025.","edition":"9"},{"key":"4163_CR11","doi-asserted-by":"publisher","first-page":"8081","DOI":"10.18632\/oncotarget.23545","volume":"9","author":"G Sun","year":"2018","unstructured":"Sun G, Dong X, Tang X, Qu H, Zhang H, Zhao E. The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. Oncotarget. 2018;9:8081\u20138. https:\/\/doi.org\/10.18632\/oncotarget.23545.","journal-title":"Oncotarget"},{"key":"4163_CR12","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040. https:\/\/doi.org\/10.1200\/JCO.1997.15.5.2040.","journal-title":"J Clin Oncol"},{"key":"4163_CR13","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1002\/cncr.34797","volume":"129","author":"L Trilla-Fuertes","year":"2023","unstructured":"Trilla-Fuertes L, G\u00e1mez-Pozo A, Nogu\u00e9 M, Busquier I, Arias F, L\u00f3pez-Campos F, et al. Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma. Cancer. 2023;129:2581. https:\/\/doi.org\/10.1002\/cncr.34797.","journal-title":"Cancer"},{"key":"4163_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0360-3016(99)00188-1","volume":"45","author":"CS Wong","year":"1999","unstructured":"Wong CS, Tsao MS, Sharma V, Chapman WB, Pintilie M, Cummings BJ. Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 1999;45:309. https:\/\/doi.org\/10.1016\/s0360-3016(99)00188-1.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4163_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1046\/j.1365-2559.2001.01161.x","volume":"39","author":"R Holm","year":"2001","unstructured":"Holm R, Skovlund E, Skomedal H, Fl\u00f8renes VA, Tanum G. Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas. Histopathology. 2001;39:43. https:\/\/doi.org\/10.1046\/j.1365-2559.2001.01161.x.","journal-title":"Histopathology"},{"key":"4163_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071606","volume":"14","author":"M Hilmi","year":"2022","unstructured":"Hilmi M, Neuzillet C, Lef\u00e8vre JH, Svrcek M, Vacher S, Benhaim L, et al. Prognostic value of Fusobacterium nucleatum after abdominoperineal resection for anal squamous cell carcinoma. Cancers (Basel). 2022;14:1606. https:\/\/doi.org\/10.3390\/cancers14071606.","journal-title":"Cancers (Basel)"},{"key":"4163_CR17","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/1097-0142(19830401)51:7<1291::AID-CNCR2820510719>3.0.CO;2-R","volume":"51","author":"WH Schraut","year":"1983","unstructured":"Schraut WH, Wang CH, Dawson PJ, Block GE. Depth of invasion, location, and size of cancer of the anus dictate operative treatment. Cancer. 1983;51:1291\u20136.","journal-title":"Cancer"},{"key":"4163_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF02586980","volume":"17","author":"ND Nigro","year":"1974","unstructured":"Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17:354. https:\/\/doi.org\/10.1007\/BF02586980.","journal-title":"Dis Colon Rectum"},{"key":"4163_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0002-9343(85)90428-0","volume":"78","author":"L Leichman","year":"1985","unstructured":"Leichman L, Nigro N, Vaitkevicius VK, Considine B, Buroker T, Bradley G, et al. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med. 1985;78:211\u20135. https:\/\/doi.org\/10.1016\/0002-9343(85)90428-0.","journal-title":"Am J Med"},{"key":"4163_CR20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","volume":"348","author":"UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research","year":"1996","unstructured":"UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348:1049\u201354.","journal-title":"Lancet"},{"key":"4163_CR21","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","volume":"14","author":"M Flam","year":"1996","unstructured":"Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527\u201339. https:\/\/doi.org\/10.1200\/JCO.1996.14.9.2527.","journal-title":"J Clin Oncol"},{"key":"4163_CR22","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","volume":"30","author":"LL Gunderson","year":"2012","unstructured":"Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, et al. Long-term update of US GI intergroup RTOG 98\u201311 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin. J Clin Oncol. 2012;30:4344\u201351. https:\/\/doi.org\/10.1200\/JCO.2012.43.8085.","journal-title":"J Clin Oncol"},{"key":"4163_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial. Lancet Oncol. 2013;14:516. https:\/\/doi.org\/10.1016\/S1470-2045(13)70086-X.","journal-title":"Lancet Oncol"},{"key":"4163_CR24","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","volume":"30","author":"D Peiffert","year":"2012","unstructured":"Peiffert D, Tournier-Rangeard L, G\u00e9rard J-P, Lemanski C, Fran\u00e7ois E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30:1941\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.35.4837.","journal-title":"J Clin Oncol"},{"key":"4163_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","volume":"72","author":"R Glynne-Jones","year":"2008","unstructured":"Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, et al. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008;72:119\u201326. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.12.012.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4163_CR26","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ijrobp.2018.04.033","volume":"101","author":"CM Jones","year":"2018","unstructured":"Jones CM, Adams R, Downing A, Glynne-Jones R, Harrison M, Hawkins M, et al. Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a National cohort. Int J Radiat Oncol Biol Phys. 2018;101:1202\u201311. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.04.033.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4163_CR27","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.ijrobp.2011.12.058","volume":"83","author":"M Ng","year":"2012","unstructured":"Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83:1455\u201362. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.12.058.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4163_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.6004\/jnccn.2010.0008","volume":"8","author":"JM Pepek","year":"2010","unstructured":"Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Canc Netw. 2010;8:123\u20139. https:\/\/doi.org\/10.6004\/jnccn.2010.0008.","journal-title":"J Natl Compr Canc Netw"},{"key":"4163_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","volume":"86","author":"LA Kachnic","year":"2013","unstructured":"Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27\u201333. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.09.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4163_CR30","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1055\/s-0037-1606118","volume":"30","author":"C Kontovounisios","year":"2017","unstructured":"Kontovounisios C, Tekkis P. Locally advanced disease and pelvic exenterations. Clin Colon Rectal Surg. 2017;30:404\u201314. https:\/\/doi.org\/10.1055\/s-0037-1606118.","journal-title":"Clin Colon Rectal Surg"},{"key":"4163_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.soc.2016.07.007","volume":"26","author":"R Adams","year":"2017","unstructured":"Adams R. Surveillance of anal canal cancers. Surg Oncol Clin North Am. 2017;26:127\u201332. https:\/\/doi.org\/10.1016\/j.soc.2016.07.007.","journal-title":"Surg Oncol Clin North Am"},{"key":"4163_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.0394","volume":"153","author":"AG Renehan","year":"2018","unstructured":"Renehan AG, Muirhead R, Sebag-Montefiore D. Limitations of the National Cancer Data Base to evaluate early-stage anal cancer treatment outcomes. JAMA Surg. 2018;153:691. https:\/\/doi.org\/10.1001\/jamasurg.2018.0394.","journal-title":"JAMA Surg"},{"key":"4163_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jamasurg.2017.3151","volume":"153","author":"CY Chai","year":"2018","unstructured":"Chai CY, Tran Cao HS, Awad S, Massarweh NN. Management of stage I squamous cell carcinoma of the anal canal. JAMA Surg. 2018;153:209\u201315. https:\/\/doi.org\/10.1001\/jamasurg.2017.3151.","journal-title":"JAMA Surg"},{"key":"4163_CR34","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s00384-020-03687-8","volume":"35","author":"TB Pedersen","year":"2020","unstructured":"Pedersen TB, Kildsig J, Serup-Hansen E, Gocht-Jensen P, Klein MF. Outcome following local excision of T1 anal cancers-a systematic review. Int J Colorectal Dis. 2020;35:1663\u201371. https:\/\/doi.org\/10.1007\/s00384-020-03687-8.","journal-title":"Int J Colorectal Dis"},{"key":"4163_CR35","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1080\/0284186X.2018.1442931","volume":"57","author":"O Leon","year":"2018","unstructured":"Leon O, Hagberg O, Johnsson A. Primary surgery with or without postoperative radiotherapy in early stage squamous cell carcinoma in the anal canal and anal margin. Acta Oncol. 2018;57:1209\u201315. https:\/\/doi.org\/10.1080\/0284186X.2018.1442931.","journal-title":"Acta Oncol"},{"key":"4163_CR36","unstructured":"NCCN Clinical Practice Guideline in Oncology. Anal Carcinoma. Version 4.2025 \u2014 May 30, 2025 [Internet]. [cited 2025 Oct 25]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/anal.pdf. Accessed 25 Oct 2025"},{"key":"4163_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","volume":"18","author":"R Glynne-Jones","year":"2017","unstructured":"Glynne-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, et al. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol. 2017;18:347\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(17)30071-2.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4163_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1463-1318.2010.02500.x","volume":"13","author":"AG Renehan","year":"2011","unstructured":"Renehan AG, O\u2019Dwyer ST. Management of local disease relapse. Colorectal Dis. 2011;13(1):44\u201352. https:\/\/doi.org\/10.1111\/j.1463-1318.2010.02500.x.","journal-title":"Colorectal Dis"},{"key":"4163_CR39","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1200\/JCO.19.03266","volume":"38","author":"S Rao","year":"2020","unstructured":"Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, et al. International Rare Cancers Initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. J Clin Oncol. 2020;38:2510\u20138. https:\/\/doi.org\/10.1200\/JCO.19.03266.","journal-title":"J Clin Oncol"},{"key":"4163_CR40","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","volume":"19","author":"S Kim","year":"2018","unstructured":"Kim S, Fran\u00e7ois E, Andr\u00e9 T, Samalin E, Jary M, El Hajbi F, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2018;19:1094\u2013106. https:\/\/doi.org\/10.1016\/S1470-2045(18)30321-8.","journal-title":"Lancet Oncol"},{"key":"4163_CR41","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1634\/theoncologist.2016-0241","volume":"22","author":"F Sclafani","year":"2017","unstructured":"Sclafani F, Morano F, Cunningham D, Baratelli C, Kalaitzaki E, Watkins D, et al. Platinum-fluoropyrimidine and paclitaxel-based chemotherapy in the treatment of advanced anal cancer patients. Oncologist. 2017;22:402\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2016-0241.","journal-title":"Oncologist"},{"key":"4163_CR42","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(24)00081-0","volume":"25","author":"S Kim","year":"2024","unstructured":"Kim S, Ghiringhelli F, de la Fouchardi\u00e8re C, Evesque L, Smith D, Badet N, et al. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study. Lancet Oncol. 2024;25:518\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(24)00081-0.","journal-title":"Lancet Oncol"},{"key":"4163_CR43","doi-asserted-by":"publisher","unstructured":"Rao S, Samalin-Scalzi E, Evesque L, et al. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM\u2011303\/InterAACT\u20112): a global, phase 3 randomised controlled trial. The Lancet. 2025;405(10495):2144\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(25)00631-2.","DOI":"10.1016\/S0140-6736(25)00631-2"},{"key":"4163_CR44","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","volume":"18","author":"VK Morris","year":"2017","unstructured":"Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:446\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(17)30104-3.","journal-title":"Lancet Oncol"},{"key":"4163_CR45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","volume":"7","author":"A Marabelle","year":"2022","unstructured":"Marabelle A, Cassier PA, Fakih M, Kao S, Nielsen D, Italiano A, et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol. 2022;7:446\u201354. https:\/\/doi.org\/10.1016\/S2468-1253(21)00382-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4163_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100529","volume":"7","author":"S Rao","year":"2022","unstructured":"Rao S, Anandappa G, Capdevila J, Dahan L, Evesque L, Kim S, et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open. 2022;7:100529. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100529.","journal-title":"ESMO Open"},{"key":"4163_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002996","volume":"9","author":"S Lonardi","year":"2021","unstructured":"Lonardi S, Prete AA, Morano F, Messina M, Formica V, Corsi DC, et al. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. J Immunother Cancer. 2021;9:e002996. https:\/\/doi.org\/10.1136\/jitc-2021-002996.","journal-title":"J Immunother Cancer"},{"key":"4163_CR48","unstructured":"M.D. Anderson Cancer Center. A Phase 2, open-label study to evaluate efficacy of combination treatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in patients with recurrent & Metastatic Human Papilloma Virus Associated Cancers [Internet]. clinicaltrials.gov; 2024 June. Report No.: NCT03439085. https:\/\/clinicaltrials.gov\/study\/NCT03439085. Accessed 6 Nov 2025"},{"key":"4163_CR49","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.annonc.2020.07.009","volume":"31","author":"D Ciardiello","year":"2020","unstructured":"Ciardiello D, Elez E, Tabernero J, Seoane J. Clinical development of therapies targeting TGF\u03b2: current knowledge and future perspectives. Ann Oncol. 2020;31:1336\u201349. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.009.","journal-title":"Ann Oncol"},{"key":"4163_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrab060","volume":"5","author":"J Engstrand","year":"2021","unstructured":"Engstrand J, de Abreu Carvalho LF, Aghayan D, Balakrishnan A, Belli A, Bj\u00f6rnsson B, et al. Liver resection and ablation for squamous cell carcinoma liver metastases. BJS Open. 2021;5:zrab060. https:\/\/doi.org\/10.1093\/bjsopen\/zrab060.","journal-title":"BJS Open"},{"key":"4163_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.6004\/jnccn.2018.7085","volume":"17","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yu X, Zhao N, Wang J, Lin C, Izaguirre EW, et al. Definitive pelvic radiotherapy and survival of patients with newly diagnosed metastatic anal cancer. J Natl Compr Canc Netw. 2019;17:29\u201337. https:\/\/doi.org\/10.6004\/jnccn.2018.7085.","journal-title":"J Natl Compr Canc Netw"},{"key":"4163_CR52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JCO.2017.74.9291","volume":"36","author":"V Col\u00f3n-L\u00f3pez","year":"2018","unstructured":"Col\u00f3n-L\u00f3pez V, Shiels MS, Machin M, Ortiz AP, Strickler H, Castle PE, et al. Anal cancer risk among people with HIV infection in the United States. J Clin Oncol. 2018;36:68\u201375. https:\/\/doi.org\/10.1200\/JCO.2017.74.9291.","journal-title":"J Clin Oncol"},{"key":"4163_CR53","unstructured":"RARECARENet - On line Analysis [Internet]. [cited 2025 Oct 25]. http:\/\/rarecarenet.istitutotumori.mi.it\/analysis.php. Accessed 25 Oct 2025"},{"key":"4163_CR54","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jgo.2021.10.008","volume":"13","author":"N VanderWalde","year":"2022","unstructured":"VanderWalde N, Moughan J, Lichtman SM, Jagsi R, Ballo M, VanderWalde A, et al. The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials. J Geriatr Oncol. 2022;13:294\u2013301. https:\/\/doi.org\/10.1016\/j.jgo.2021.10.008.","journal-title":"J Geriatr Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04163-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04163-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:09:52Z","timestamp":1774415392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04163-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4163"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04163-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M\u00f3nica Guillot Morales: reports speaker fee from Merck, MSD, and Servier; advisory board fee from Roche\n                      ,\n                      and GlaxoSmithKline S.A. Ismael Ghanem Ca\u00f1ete: reports speaker fee from Merck, Amgen, and MSD and advisory board\u2013speaker fee from Servier and AstraZeneca. Jer\u00f3nimo Jim\u00e9nez-Castro: reports Speaker from Servier, Merck and Amgen. Joan Maurel Santasusana: reports personal fees from Advance Medical, Amgen, Cancer Expert Now and MSD; advisory board fee from Delcath Systems Inc, GlaxoSmithKline SA (GSK), and Incyte Biosciences International; grant from Amgen, Guardant, Incyte, Merck, and Terumo and non-financial support from GEMCAD. Ana Fern\u00e1ndez Montes, Julen Fern\u00e1ndez-Plana, M\u00aa Auxiliadora G\u00f3mez-Espa\u00f1a, Mireia Gil Raga, Ignacio Juez Martel, and Eduardo Polo Marqu\u00e9s have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}